Skip to main content
      RT @drdavidliew: Each line is a different country's JAK inhibitor for RA registry, looking at drug stopped for adverse e

      David Liew drdavidliew

      4 years 5 months ago
      Each line is a different country's JAK inhibitor for RA registry, looking at drug stopped for adverse events. Why all the variation? (Until we sort that out, we'll struggle to assess JAKi post-marketing safety...) @k_lauper's JAK-pot study POS0093 #EULAR2021 @RheumNow https://t.co/YykoG7LlEw
      RT @uptoTate: German SpA Inception Cohort analyses: TNFi assc w/ ⬇️ sacroiliitis and spinal dz progression in axSpA

      Dr. Rachel Tate uptoTate

      4 years 5 months ago
      German SpA Inception Cohort analyses: TNFi assc w/ ⬇️ sacroiliitis and spinal dz progression in axSpA pts, but the effect is evident starting between 2 and 4 years post tx induction. #EULAR2021 Abstracts #OP0137 & #OP0139 @RheumNow https://t.co/uR9rug6zqI https://t.co/xF3wcxm4cf https://t.co/lEsUvOSJ6K
      RheumNow’s expanded coverage of the #EULAR2021 Annual meeting is sponsored in part by Novartis, Bristol Myers Squibb,

      Dr. John Cush RheumNow

      4 years 5 months ago

      RheumNow’s expanded coverage of the #EULAR2021 Annual meeting is sponsored in part by Novartis, Bristol Myers Squibb, Janssen. All content chosen by RheumNow & its Faculty.

      RT @uptoTate: @jeffsparks wahooo! Congrats on the #EULAR2021 clinical science award recognition!

      Dr. Rachel Tate uptoTate

      4 years 5 months ago
      @jeffsparks wahooo! Congrats on the #EULAR2021 clinical science award recognition!
      RT @ERheumat: #EULAR2021 #EULAR21 #eular #spondyloarthritis
      I have always thought we named nr-axSPA wrongly - Tends to

      EnvisionRheumat ERheumat

      4 years 5 months ago
      #EULAR2021 #EULAR21 #eular #spondyloarthritis I have always thought we named nr-axSPA wrongly - Tends to trivialise its gravity and importance Shouldn’t it be our goal to diagnose all SpA at the nr-axSPA stage @deodhara @NigilHaroon https://t.co/zwKI1o9WcO
      RT @_connectedcare: Patient profiles have changed in clinical trials of PsA #EULAR2021 https://t.co/6l2RfOPkSq

      Dr Irwin Lim _connectedcare

      4 years 5 months ago
      Patient profiles have changed in clinical trials of PsA #EULAR2021 https://t.co/6l2RfOPkSq
      RT @MeralElRamahiMD: #EULAR2021: AxSpA patients with greater patient-reported pain and spinal pain relative to axPsA pat

      Meral K. El Ramahi, MD MeralElRamahiMD

      4 years 5 months ago
      #EULAR2021: AxSpA patients with greater patient-reported pain and spinal pain relative to axPsA patients among real-world patients in CorEVitas' Psa/Spa observational Registry per Dr. Mease's oral abstract presentation. @RheumNow https://t.co/YEdhd7x6cb
      RT @MeralElRamahiMD: #EULAR2021 - Key points from Dr. Mease's oral abstract:
      ⭐️AxSpA pts were younger & more li

      Meral K. El Ramahi, MD MeralElRamahiMD

      4 years 5 months ago
      #EULAR2021 - Key points from Dr. Mease's oral abstract: ⭐️AxSpA pts were younger & more likely to be male & have a hx of uveitis & IBD ⭐️AxSpA pts had less exposure to prior therapies relative to axPsA pts ⭐️AxSpA assoc w/ > spinal pain regardless of b/tsDMARD status @Rheumnow
      RT @MeralElRamahiMD: #EULAR2021: AxSpA patients more likely to experience IBD and uveitis whereas axPsA more likely to e

      Meral K. El Ramahi, MD MeralElRamahiMD

      4 years 5 months ago
      #EULAR2021: AxSpA patients more likely to experience IBD and uveitis whereas axPsA more likely to experience dactylitis and enthesitis per Dr. Philip Mease's study among real-world patients in CorEVitas' Psa/Spa Registry. @RheumNow https://t.co/g2m5fylFJj
      ×